T1	Participants 25 53	patients with anemia and CKD
T2	Participants 118 161	patients with chronic kidney disease (CKD).
T3	Participants 818 860	750 patients with CKD stages 1 to 5 and 5D
T4	Participants 1186 1245	713 patients received ferumoxytol, and 711 received placebo
T5	Participants 1111 1184	750 randomly assigned patients with CKD, 60% were not on dialysis therapy
T6	Participants 1258 1376	420 adverse events reported; 242 in 152 patients (21.3%) with ferumoxytol and 178 in 119 patients (16.7%) with placebo
T7	Participants 2083 2128	anemic patients with CKD stages 1 to 5 and 5D
